Search results for " ACTIVATION"

showing 10 items of 1535 documents

Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro

2012

Maintaining graft versus leukemia (GvL) and antivirus responses of cytotoxic T cells (CTLs) while suppressing graft-versus-host disease (GvHD) remains a challenge after allogeneic bone marrow transplantation. Clinical observations indicate that combining glucocorticoids with multi-tyrosine-kinase inhibitors could be a successful therapeutic approach. We and others have shown that the BCR-ABL/SRC kinase inhibitor dasatinib may enhance or suppress T cells in vitro. In this report, we evaluated combination effects of dasatinib and dexamethasone on CD3 + and virus-specific CD8 + T cells directly ex vivo and on antigen-specific leukemia-reactive and alloreactive CD8 + T cell clones. Functional o…

Cytotoxicity ImmunologicHerpesvirus 4 HumanCancer ResearchNaive T cellT cellDasatinibDrug Evaluation PreclinicalReceptors Antigen T-CellCytomegalovirusApoptosisT-Cell Antigen Receptor SpecificityBiologyLymphocyte ActivationCell DegranulationDexamethasoneAntigenHLA AntigensT-Lymphocyte SubsetsGeneticsmedicineHumansCytotoxic T cellAntigens ViralProtein Kinase InhibitorsMolecular BiologyCells CulturedDegranulationDrug SynergismT-Lymphocytes Helper-InducerCell BiologyHematologyDasatinibThiazolesPyrimidinesmedicine.anatomical_structureImmunologyCancer researchCytokinesK562 CellsMemory T cellCell DivisionCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugExperimental Hematology
researchProduct

Lymphokine activated killer cells.

1989

Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma …

Cytotoxicity ImmunologicLymphokine-activated killer cellTumor-infiltrating lymphocytesmedicine.medical_treatmentLymphokineHematologyGeneral MedicineImmunotherapyBiologyNatural killer T cellMajor histocompatibility complexLymphocyte ActivationTumor antigenKiller Cells NaturalImmunologymedicinebiology.proteinCytotoxic T cellAnimalsHumansInterleukin-2Killer Cells Lymphokine-ActivatedBlut
researchProduct

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

2015

Abstract Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design: Twenty-seven patients with CEA-expressing carcinomas were recruited: 15 patients with measurable disease (arm-I) and 12 patients without radiological evidence of disease (arm-II). Six intramuscular vaccinations of naked DNA (1 mg/dose) were administered up to week 12. Clinical and immunologic follow-up was up to week 64 or clinical/radiological disease. Results: DOM-specific immune responses demonstrated successful vaccine delivery. All p…

Cytotoxicity ImmunologicMaleCancer ResearchCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesArticleDNA vaccination03 medical and health sciences0302 clinical medicineCarcinoembryonic antigenImmune systemVaccines DNAMedicineHumansAdverse effectbiologybusiness.industryCarcinomaCancermedicine.diseaseCarcinoembryonic AntigenVaccinationOncologyNaked DNA030220 oncology & carcinogenesisImmunologybiology.proteinFemaleAntibodybusinessOligopeptides030215 immunology
researchProduct

H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the hepatitis B virus core gene products.

2000

The function of the secretory core gene product (HBeAg) of the human hepatitis B virus (HBV) is unknown. It has been proposed that this protein may be passed from the mother to her offspring at the perinatal stage where it might induce immune tolerance. In a previous study we have shown that the murine placenta presents an efficient barrier for the HBe protein and that H-2(b) mice born to HBeAg-positive transgenic mothers do not develop tolerance of specific cytotoxic T cells. In the present work we demonstrate that transgenic mice expressing high serum levels of HBeAg secrete only small amounts of this protein into their milk and excrete minute amounts of the viral gene product in their ur…

Cytotoxicity ImmunologicMaleHepatitis B virusT cellvirusesT-LymphocytesMothersMice TransgenicBiologymedicine.disease_causeLymphocyte ActivationImmune toleranceMiceImmune systemVirologymedicineImmune ToleranceCytotoxic T cellAnimalsHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusMice Inbred BALB CH-2 Antigensvirus diseasesT-Lymphocytes Helper-InducerHepatitis Bmedicine.diseaseHepatitis BVirologydigestive system diseasesPeptide Fragmentsmedicine.anatomical_structureMilkHBeAgAnimals NewbornImmunologyFemaleCD8T-Lymphocytes CytotoxicVirology
researchProduct

P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.

2008

Monoclonal antibodies (mAbs), successfully adopted in the treatment of several haematological malignancies, have proved almost ineffective in multiple myeloma (MM), because of the lack of an appropriate antigen for targeting and killing MM cells. Here, we demonstrate that PSGL1, the major ligand of P-Selectin, a marker of plasmacytic differentiation expressed at high levels on normal and neoplastic plasma cells, may represent a novel target for mAb-mediated MM immunotherapy. The primary effectors of mAb-induced cell-death, complement-mediated lysis (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), were investigated using U266B1 and LP1 cell-lines as models. Along with immunolo…

Cytotoxicity ImmunologicMembrane Glycoproteinsmieloma multiplo; ab therapy; PSGL-1ab therapyAntibody-Dependent Cell CytotoxicityDrug Evaluation PreclinicalAntibodies MonoclonalBone Marrow CellsSettore MED/08 - Anatomia Patologicamultiple myelomaDrug Delivery SystemsCell Line TumorHumanscomplementimmunotherapymieloma multiploPSGL-1ADCCComplement Activationmonoclonal antibodie
researchProduct

An Ovalbumin Peptide-Specific Cytotoxic T Cell Clone with Antigen Self-Presentation Capacity Uses Two Distinct Mechanisms to Kill Target Cells

1993

Abstract Cloned 10BK.1 T cells with specificity for the ovalbumin peptide OVA257-264 are representative of a novel cell type within the CD8 + subset of T cells. In the presence and in the absence of added antigen presenting cells these T cells react toward antigen (Ag) by proliferation and lymphokine production. These data suggest self-presentation of the Ag by 10BK.1 cells. Here we present evidence that 10BK.1 cells exhibit cytotoxic activity that involves two different cytotoxic effector mechanisms. (i) One mechanism is fast killing activity, apparent within 4 hr. Constitutive mouse T cell-specific proteinase-1 (MTSP-1) activity, constitutive expression of MTSP-1 RNA, increased by Ag chal…

Cytotoxicity ImmunologicPore Forming Cytotoxic ProteinsOvalbuminImmunologyAntigen presentationAntigen-Presenting CellsBiologyCytoplasmic GranulesLymphocyte ActivationGranzymesCell LineMiceInterleukin 21AntigenAnimalsCytotoxic T cellIL-2 receptorAntigen-presenting cellLymphotoxin-alphaMembrane GlycoproteinsCD40PerforinTumor Necrosis Factor-alphaSerine EndopeptidasesDegranulationMolecular biologyClone Cellsbiology.proteinInterleukin-2T-Lymphocytes CytotoxicCellular Immunology
researchProduct

Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo.

2006

The factors controlling clonal dominance of cytotoxic T lymphocyte (CTL) responses are currently not well understood. To study the functional impact of the strength of the interaction of a T cell with an antigen-presenting cell in this context, we established a new mouse model comprised of two T cell receptor (TCR)-transgenic strains expressing the identical TCR in differing amounts, hence providing two CTL clones with different avidities but identical specificity and affinity. Utilizing this new model, we show that upon antigen challenge higher-avidity CTL expand at the expense of moderate-avidity CTL in vivo if present in equal numbers. Beyond this, moderate-avidity T cells can also contr…

Cytotoxicity ImmunologicT cellImmunologyReceptors Antigen T-CellPriming (immunology)chemical and pharmacologic phenomenaMice TransgenicStreptamerImmunodominanceBiologyLymphocyte ActivationMiceAntigenmedicineImmunology and AllergyCytotoxic T cellAnimalsAntigen PresentationStem CellsT-cell receptorhemic and immune systemsFlow CytometryAdoptive TransferCell biologyMice Inbred C57BLCTL*medicine.anatomical_structureImmunologyT-Lymphocytes CytotoxicEuropean journal of immunology
researchProduct

Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2

1981

The site of action of the immunosuppressive drug cyclosporin A in in vitro cytotoxic allograft responses has been localized. General cytotoxic effects of the drug on proliferating T cells became apparent at concentrations of 500-1000 ng/ml, while selective effects were observed at concentrations of 10-100 ng/ml. The selective effects included a blockade of interleukin 2 release from activated T helper cells on the one hand and inhibition of interleukin 1 release from splenic adherent cells on the other. While cyclosporin A did not interfere with the intracellular events required for the activation and subsequent clonal expansion of alloreactive T cells, the lack of interleukin 1 and interle…

Cytotoxicity ImmunologicT-LymphocytesImmunologyCyclosporinsPharmacologyBiologyLymphocyte ActivationMiceInterleukin 21Cyclosporin aAnimalsImmunology and AllergyInterleukin 5Interleukin 4Interleukin 3Mice Inbred BALB CProteinsInterleukinInterleukin 33Protein BiosynthesisMice Inbred CBAInterleukin 12Interleukin-2Lymphocyte Culture Test MixedImmunosuppressive AgentsInterleukin-1European Journal of Immunology
researchProduct

RNA Transfer by Electroporation into Mature Dendritic Cells Leading to Reactivation of Effector-Memory Cytotoxic T Lymphocytes: A Quantitative Analys…

2005

Previous studies have analyzed transfer of RNA-encoded tumor-associated antigens (TAAs) into immature dendritic cells (DCs) because of their exceptional ability to internalize antigens. Concerns have been raised regarding the use of immature DCs in clinical studies because of their capacity to tolerize T cells. Therefore, we focused on optimizing RNA transfer into mature DCs using the method of electroporation and obtained high protein expression in 90% of mature DCs. Particular emphasis was placed on quantifying RNA transfer. Reconstitution of peptide-MHC (pMHC) ligands on RNA-pulsed DCs was measured with the help of effector-memory cytotoxic T lymphocytes (CTLs) specific for the melanoma-…

Cytotoxicity Immunologicchemical and pharmacologic phenomenaBiologyLymphocyte ActivationTransfectionEpitopeAntigenCell Line TumorDrug DiscoveryGeneticsHumansCytotoxic T cellMelanomaMolecular BiologyPharmacologyEffectorElectroporationRNAhemic and immune systemsDendritic CellsTransfectionMolecular biologyElectroporationPhenotypedendritic cells; RNA transfection; electroporation; effector-memory cytotoxic T lymphocytes; peptide-MHC ligands; tumor immunotherapy; melanoma; tyrosinase; CDK4; EGFPRNAMolecular MedicineImmunotherapyRNA transfectionT-Lymphocytes CytotoxicMolecular Therapy
researchProduct

Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.

2013

Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of human T cells are unimpaired in the absence of arginine. We then analyzed CD8(+) T cell activation…

Cytotoxicity Immunologiclcsh:MedicineCD8-Positive T-LymphocytesARGINASELymphocyte ActivationGranzymesInterleukin 21Cytotoxic T cellIL-2 receptorlcsh:ScienceCells CulturedMultidisciplinarybiologyT CellsChemotaxisVaccinationCOFILINCD28Natural killer T cellCANCERmedicine.anatomical_structureMedicineScience & Technology - Other TopicsImmunotherapyResearch ArticleTumor ImmunologyEXPRESSIONINFILTRATING LYMPHOCYTESCARCINOMAGeneral Science & TechnologyT cellImmune CellsImmunologyArginineImmune SuppressionDENDRITIC CELLSImmunomodulationInterferon-gammaMART-1 AntigenMULTIPLE-MYELOMAMD MultidisciplinarymedicineImmune ToleranceHumansCalcium SignalingAntigen-presenting cellBiologyCell ProliferationCD40Science & TechnologyMULTIDISCIPLINARY SCIENCESPerforinlcsh:RImmunityImmunoregulationIN-VITROImmunologic SubspecialtiesMolecular biologybiology.proteinMYELOID SUPPRESSOR-CELLSClinical ImmunologyTumor Escapelcsh:QT-Lymphocytes CytotoxicPLoS ONE
researchProduct